SCHEMBL572669

SCHEMBL572669

O=[N+]([O-])c1cc(C(F)(F)F)cnc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.61
CYP3A4 P08684 3/20 0.61
ALDH1A1 P00352 3/20 0.61
TSHR P16473 2/20 0.61
HPGD P15428 1/20 0.61
ALOX15 P16050 1/20 0.61
HIF1A Q16665 1/20 0.61
TXNRD1 Q16881 1/20 0.61
TXNRD3 Q86VQ6 1/20 0.61
TXNRD2 Q9NNW7 1/20 0.61
FGFR4 P22455 1/20 0.51
MAPT P10636 6/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
GAA P10253 2/20 0.48
NPC1 O15118 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C19 P33261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29439786 1.00 TDP1 (0.61) TDP1CYP3A4ALDH1A1TSHRHPGD
SCHEMBL4047380 0.83 ALDH1A1 (0.43) TDP1CYP3A4ALDH1A1TSHRHPGD
SCHEMBL11188525 0.81 ALDH1A1 (0.53) TDP1CYP3A4ALDH1A1TSHRHPGD
SCHEMBL18665461 0.81 ALDH1A1 (0.53) TDP1CYP3A4ALDH1A1TSHRHPGD
SCHEMBL572768 0.79 CYP3A4 (0.51) TDP1CYP3A4ALDH1A1TSHRHPGD
SCHEMBL573358 0.79 ALDH1A1 (0.51) TDP1CYP3A4ALDH1A1TSHRHPGD
SCHEMBL30788051 0.79 ALDH1A1 (0.51) TDP1CYP3A4ALDH1A1TSHRHPGD
SCHEMBL10280706 0.79 ALDH1A1 (0.51) TDP1CYP3A4ALDH1A1TSHRHPGD
SCHEMBL2371582 0.79 ALDH1A1 (0.51) TDP1CYP3A4ALDH1A1TSHRHPGD
SCHEMBL30358860 0.79 CYP3A4 (0.51) TDP1CYP3A4ALDH1A1TSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 427 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115991873-A Low-dielectric fluorinated aromatic polyimide film and preparation method thereof 慧创(东莞)材料技术有限责任公司 2023-04-21 CN claimed
US-20190048024-A1 SYNTHETIC PROCESSES AND INTERMEDIATES TAXIS PHARMACEUTICALS, INC. (US) 2019-02-14 US claimed
EP-3419967-A1 SYNTHETIC PROCESSES AND INTERMEDIATES Taxis Pharmaceuticals, Inc. (US) 2019-01-02 EP claimed
WO-2017147316-A1 SYNTHETIC PROCESSES AND INTERMEDIATES TAXIS PHARMACEUTICALS, INC. (US) 2017-08-31 WO claimed
JP-5170742-A None JP disclosed
JP-58170759-A None JP disclosed
WO-2026106929-A1 DIHYDROQUINAZOLINES USEFUL AS CYTOMEGALOVIRUS ANTIVIRAL AGENTS ASSEMBLY BIOSCIENCES, INC. (US) 2026-05-21 WO disclosed
US-12617789-B2 Small molecular inhibitors of NF-κb inducing kinase JANSSEN PHARMACEUTICA NV (BE) 2026-05-05 US disclosed
US-12610730-B2 Metal complex and light emitting device CITY UNIVERSITY OF HONG KONG (HK) 2026-04-21 US disclosed
US-20260103464-A1 CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2026-04-16 US disclosed
EP-4720055-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF Arcus Biosciences, Inc. (US) 2026-04-08 EP disclosed
EP-4705292-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF Arcus Biosciences, Inc. (US) 2026-03-11 EP disclosed
US-4831148-A DIAZOTISING A 3-AMINO-2-HALOPYRIDINE IN PRESENCE OF HYDROGEN FLUORIDE CIBA-GEIGY CORPORATION (US) 1989-05-16 US disclosed
EP-0272824-A2 Chemical compounds IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1988-06-29 EP disclosed
EP-0178260-A2 Process for the preparation of fluorinated pyridine derivatives CIBA-GEIGY AG (CH) 1986-04-16 EP disclosed
JP-S58170759-A 2-MERCAPTO-3-SUBSTITUTED-5-TRIFLUOROMETHYLPYRIDINE COMPOUND ISHIHARA SANGYO KAISHA LTD 1983-10-07 JP disclosed
US-4393212-A ADRENERGIC BLOCKING AGENTS MERCK & CO., INC. (US) 1983-07-12 US disclosed
US-4294969-A COUPLING N-BROMOSUCCINIMIDE AND A 2-BROMOPYRIDINE MERCK & CO., INC. (US) 1981-10-13 US disclosed
US-4279913-A ANTIARRYTHMIA, HYPOTENSIVE MERCK & CO., INC. (US) 1981-07-21 US disclosed
EP-0003278-A1 Polysubstituted-2-(3-loweralkylamino-2-R0-propoxy)pyridines, process for preparing the same, and pharmaceutical compositions containing the same MERCK & CO. INC. (US) 1979-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190048024-A1 SYNTHETIC PROCESSES AND INTERMEDIATES CYP11B1, CYP11B2, REN TDP1 3664/4885CYP3A4 40/4885ALDH1A1 1693/4885
US-12610730-B2 Metal complex and light emitting device OPRD1, OCIAD2, ORC3 TDP1 1841/4885CYP3A4 737/4885ALDH1A1 4413/4885
US-12617789-B2 Small molecular inhibitors of NF-κb inducing kinase IRAK3, IKBKB, IKBKG TDP1 3147/4885CYP3A4 4654/4885ALDH1A1 3824/4885
US-20260103464-A1 CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES CBR3, CYCS, CBR1 TDP1 4527/4885CYP3A4 331/4885ALDH1A1 2267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.